Tag: Heartflow

HeartFlow Announces Collaborative Research Agreement with Imperial College London

REDWOOD CITY, Calif.–(BUSINESS WIRE)– HeartFlow, Inc. today announced that it has entered into a collaborative research agreement with Imperial College London. The collaboration will enable experts from HeartFlow and Imperial to work side-by-side on joint projects in the areas of medical imaging and deep learning. The company’s non-invasive HeartFlow® FFRct Analysis leverages deep […]

Bay Area’s HeartFlow Scores $240M

HeartFlow Completes Series E Financing, Securing $240 Million Proceeds Will Support Commercialization of HeartFlow® FFRct Analysis, Continued Technology Innovation and Additional Clinical Studies REDWOOD CITY, Calif.–(BUSINESS WIRE)– HeartFlow. today announced the closing of its Series E financing, securing $240 million. The company will use the proceeds from this financing to ramp up commercial […]

HeartFlow Announces Decision by HCSC and Additional BlueCross BlueShield Companies to Issue New Positive Medical Policies for Non-Invasive HeartFlow FFRct Analysis

REDWOOD CITY, Calif.–(BUSINESS WIRE)– HeartFlow today announced that Health Care Service Corporation (HCSC), which operates Blue Cross and Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma and Texas, has issued a medical policy for the HeartFlow® FFRct Analysis, a first-of-its-kind non-invasive technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD). HCSC […]

HeartFlow Announces Decision by Centers for Medicare & Medicaid Services to Assign a New Technology Payment Classification to HeartFlow® FFRct Analysis

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory Payment Classification (APC) for the HeartFlow® FFRct Analysis, a first-of-its-kind non-invasive technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD). Under the APC payment system, […]

Corindus Evaluates Incorporating HeartFlow Technology with CorPath GRX System

WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will incorporate the HeartFlow® FFRct Analysis in a case series of robotic-assisted percutaneous coronary intervention (PCI) procedures with the CorPath® GRX System to evaluate the feasibility and utility of clinical decision support. “We are […]

HeartFlow Announces Positive Medical Coverage Decisions on Non-Invasive HeartFlow® FFRct Analysis from Anthem Blue Cross Blue Shield, Blue Shield of California and Blue Cross and Blue Shield of Alabama

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that Anthem Blue Cross Blue Shield, Blue Shield of California, and Blue Cross and Blue Shield of Alabama have each issued a positive medical policy for the HeartFlow® FFRct Analysis, a first-of-its-kind noninvasive technology that helps clinicians diagnose and treat patients with suspected coronary artery […]

HeartFlow Announces Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on Non-Invasive HeartFlow® FFRct Analysis for Coronary Artery Disease

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ), Blue Cross Blue Shield of Arizona, Blue Cross of Idaho and Blue Cross Blue Shield of Kansas City have each issued a positive medical policy for the HeartFlow® FFRct Analysis, a first-of-its-kind noninvasive technology […]